{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-073904","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.211061+00:00","generated_at":"2026-05-23T19:45:51.339182+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Intellia amends bylaws to adopt majority voting for uncontested director elections","bullets":["Majority vote standard adopted for uncontested director elections; plurality retained for contested elections.","Amended bylaws include proxy solicitation procedures consistent with SEC Rule 14a-19.","Changes effective April 3, 2025; Board approved on recommendation of governance committee.","Other clarifying and procedural amendments also made to the bylaws."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-073904","json":"https://secwatch.observer/filing/0001193125-25-073904.json","markdown":"https://secwatch.observer/filing/0001193125-25-073904.md","text":"https://secwatch.observer/filing/0001193125-25-073904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525073904/0001193125-25-073904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000119312525073904/d901196d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:45:51.339182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}